Compare Amgen, Inc. (AMGN) vs Aterian Inc (ATER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Aterian Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Aterian Inc trades at $1.14 (market cap $12.44M). The key difference: Amgen, Inc. is far larger — about 15765.3× Aterian Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| AMGN | ATER | |
|---|---|---|
Market Cap | $196.12B | $12.44M |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $1.45 |
52-Week Low | $271.18 | $0.54 |
Enterprise Value | $241.41B | $13.02M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Aterian (ATER) trades at $1.15, down 3.36% with a bullish technical signal despite negative profitability. Revenue has declined from $221M in 2022 to $69M in 2025, with net losses narrowing but persisting. The company is pursuing an asset sale, with proxy advisors recommending stockholders vote for transactions expected to return $0.85-$1.14 per share. Analyst sentiment is split evenly between Buy and Hold ratings.
The outlook hinges on the successful asset sale providing shareholder returns, but fundamental challenges remain with sustained losses and cash burn. Investment opportunity exists in the potential special dividend, while risks include ongoing operational losses and competitive pressures in consumer products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →
